Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroVax in pediatric multiple sclerosis
NCT02200718Phase 1Unknown
- Sponsor
- Immune Response BioPharma, Inc.
- Start
- Dec 2020
- Primary completion
- Nov 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing NeuroVax with IFA Placebo (2 arms). Primary endpoint: MRI & WBC measurements at 26 weeks. Status: unknown.
02
Drugs
IR208
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02200718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02200718.